Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy - Diagnostic-predictive role of 64CuCl2 in urothelial tumors

开始日期2021-03-08

申办/合作机构

Ente Ospedaliero Ospedali Galliera

EUCTR2018-004667-30-IT

/ Not yet recruiting临床2期IIT

Diagnostic and clinical value of 64CuCl2 in HGG/DIPG - 64CuCl2 in high grade glioma

开始日期2019-09-16

申办/合作机构

Ente Ospedaliero Ospedali Galliera

EUCTR2019-000744-10-IT

/ Unknown status临床3期

Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer.Phase III multicenter, sponsored, interventional open-label clinical study, with prospective enrollment. - 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer

开始日期2019-06-28

申办/合作机构

A.C.O.M. - Advanced Center Oncology Macerata - Srl

100 项与氯化铜[64Cu] 相关的临床结果

登录后查看更多信息

100 项与氯化铜[64Cu] 相关的转化医学

登录后查看更多信息

100 项与氯化铜[64Cu] 相关的专利（医药）

登录后查看更多信息

项与氯化铜[64Cu] 相关的文献（医药）

2023-01-01·Frontiers in medicine

Modifications in cellular viability, DNA damage and stress responses inflicted in cancer cells by copper-64 ions.

Article

作者: Stan, Miruna ; Niculae, Dana ; Mustăciosu, Cosmin ; Cornoiu, Maria R ; Manda, Gina ; Temelie, Mihaela ; Neagoe, Ionela ; Cocioabă, Diana ; Dinischiotu, Anca ; Leonte, Radu A ; Serban, Radu M ; Chilug, Livia E ; Dobre, Maria ; Niculae, Dragoș A

Due to combined therapeutical emissions, a high linear energy transfer Auger-electrons with the longer ranged β^- particles, ⁶⁴Cu-based radiopharmaceuticals raise particular theragnostic interest in cancer, by joined therapeutic and real-time PET imaging properties. The in vitro study aimed to investigate the biological and molecular background of ⁶⁴CuCl₂ therapy by analyzing the damages and stress responses inflicted in various human normal and tumor cell lines. Colon (HT29 and HCT116) and prostate carcinoma (DU145) cell lines, as well as human normal BJ fibroblasts, were treated up to 72 h with 2-40 MBq/mL ⁶⁴CuCl₂. Radioisotope uptake and retention were assessed, and cell viability/death, DNA damage, oxidative stress, and the expression of 84 stress genes were investigated at various time points after [⁶⁴Cu]CuCl₂ addition. All the investigated cells incorporated ⁶⁴Cu ions similarly, independent of their tumoral or normal status, but their fate after exposure to [⁶⁴Cu]CuCl₂ was cell-dependent. The most striking cytotoxic effects of the radioisotope were registered in colon carcinoma HCT116 cells, for which a substantial decrease in the number of metabolically active cells, and an increased DNA damage and oxidative stress were registered. The stress gene expression study highlighted the activation of both death and repair mechanisms in these cells, related to extrinsic apoptosis, necrosis/necroptosis or autophagy, and cell cycle arrest, nucleotide excision repair, antioxidant, and hypoxic responses, respectively. The in vitro study indicated that 40 MBq/mL [⁶⁴Cu]CuCl₂ delivers a therapeutic effect in human colon carcinoma, but its use is limited by harmful, yet lower effects on normal fibroblasts. The exposure of tumor cells to 20 MBq/mL [⁶⁴Cu]CuCl₂, might be used for a softer approach aiming for a lower radiotoxicity in normal fibroblasts as compared to tumor cells. This radioactive concentration was able to induce a persistent decrease in the number of metabolically active cells, accompanied by DNA damage and oxidative stress, associated with significant changes in stress gene expression in HCT116 colon cancer cells.

2022-04-01·Nuclear medicine and molecular imaging

Recent Advances in Cancer Imaging with 64CuCl2 PET/CT

Review

作者: Peng, Fangyu

Copper is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (⁶⁴CuCl₂) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using ⁶⁴CuCl₂ as a radiotracer for cancer imaging with PET. Radiation dosimetry study in humans demonstrated radiation safety of ⁶⁴CuCl₂. Recently, ⁶⁴CuCl₂ was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Based on the findings from the preclinical research studies, ⁶⁴CuCl₂ PET/CT also holds potential for diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and detection of intracranial metastasis of copper-avid tumors based on low physiological background of radioactive copper uptake in the brain. Copper-64 radionuclide emits both β⁺ and β^- particles, suggesting therapeutic potential of ⁶⁴CuCl₂ for radionuclide cancer therapy of copper-avid tumors. Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of ⁶⁴CuCl₂ and ⁶⁷CuCl₂ for cancer imaging and radionuclide therapy.

2020-09-01·Annals of nuclear medicine4区 · 医学

Preclinical PET imaging study of lung cancer with 64CuCl2

4区 · 医学

Article

作者: Wang, Qiang ; Song, Dongli ; Ma, Xiaowei ; Jiang, Lei ; Wu, Xiaodong

OBJECTIVE:

Human copper transporter 1 (CTR1) has been proven to be overexpressed in many types of cancer cells, and copper (II)-64 chloride (⁶⁴CuCl₂) has been used as an effective tracer for positron emission tomography (PET) imaging in tumor-bearing animal models. Thus, this study aimed to investigate the potential application of ⁶⁴CuCl₂ in PET imaging of lung cancer through targeting CTR1.

METHODS:

The expression of CTR1 in a series of lung cancer cell lines was identified by quantitative real-time polymerase chain reaction (Q-PCR), western blot, enzyme-linked immunosorbnent assay (ELISA), and immunofluorescent staining. Then in vitro cell uptake assay of ⁶⁴CuCl₂ was investigated in human lung cancer cell lines with different levels of CTR1 expression. Small animal PET imaging and quantitative analysis were performed in human lung cancer tumor-bearing mice after intravenous injection of ⁶⁴CuCl₂, respectively.

RESULTS:

The CTR1 expression in multiple human lung cancer cells was identified and confirmed, and H1299 cell lines with high CTR1 expression, H460 with moderate CTR1, and H1703 with low CTR1 were selected for further experiments. In vitro cellular uptake assay displayed that the ⁶⁴CuCl₂ uptake by these three kinds of cells was positively correlated with their CTR1 expressed levels. The blocking experiments testified the specificity of ⁶⁴CuCl₂ to target CTR1. Moreover, small animal PET imaging and quantitative results showed that ⁶⁴CuCl₂ accumulation in H1299, H460, and H1703 tumor-bearing mice were consistent with CTR1 levels and cell uptake experiments.

CONCLUSIONS:

The expression of CTR1 in human lung cancer xenograft model could be successfully visualized by ⁶⁴CuCl₂ PET examination. With the expected growth of PET/CT examination to be an essential strategy in clinical lung cancer management, ⁶⁴CuCl₂ has the potential to be a promising PET imaging agent of lung cancer.

项与氯化铜[64Cu] 相关的新闻（医药）

2022-09-05

·PRNewswire

Global $1.31 Bn Prostate Cancer Nuclear Medicine Diagnostics Market to 2028: Opportunities in the Growing Use of Radiopharmaceuticals

DUBLIN, Sept. 5, 2022 /PRNewswire/ -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028. Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period. Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging. Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share. Key Market Dynamics Market Drivers Rising Prevalence of Prostate Cancer Surging Demand for Early and Precise Diagnosis of Prostate Cancer Market Restraints High Cost Related to the Prostate Cancer Diagnostics and Treatment Market Opportunities Growing Use of Radiopharmaceuticals in Prostate Cancer Future Trends Increasing Research Activities for Development of Innovative Imaging Agents Company Profiles Blue Earth Diagnostics Limited ImaginAB Curium Jubilant Radiopharma NCM-USA LLC ABX Advanced Biochemical Compounds GmbH Telix Pharmaceuticals Ltd. Novartis AG Theragonostics Lantheus Medical Imaging Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

诊断试剂

100 项与氯化铜[64Cu] 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
膀胱癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
肌肉疾患	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
尿路上皮癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2021-03-08
弥漫内生性脑桥神经胶质瘤	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2019-09-16
前列腺癌	临床2期	意大利	Ente Ospedaliero Ospedali Galliera	2015-11-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2024	临床1期	复发性胶质母细胞瘤 64CuCl2 PET/CT scan	21	64CuCl2	襯廠範積餘鬱顧壓餘餘(衊遞鏇淵齋簾積窪積廠) = 觸蓋窪觸齋蓋蓋遞鏇膚憲鹹鏇繭積鏇顧鬱構衊 (淵積衊壓鏇齋餘簾獵蓋 ) 更多	积极	2024-09-27
EANM2021	N/A	高级别胶质瘤	10	64CuCl2	遞襯顧糧網積醖構鏇網(膚艱願選餘鑰艱觸願鹹) = The PET-based volumes were more similar to the T1- than to the FLAIR-derived ones (median of 2.95, 6.31, and 2,67 ml for T1, FLAIR, and PET, respectively) 壓獵鑰壓網夢衊窪鹽範 (淵蓋顧糧積夢構醖顧鹹 ) 更多	-	2021-09-24